As a subset of the combined outcome, myocardial infarction was explored as a significant risk reduction from antiplatelet agents (OR: 0.77), while the other components of the primary end point, including stroke, coronary revascularization, and cardiovascular death, tended to decrease; however, they did not reach statistical significance.
← all excerpts
Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
1
—
—